FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667065> ?p ?o ?g. }

• W4385667065 endingPage "e64762bd" @default.
• W4385667065 startingPage "e64762bd" @default.
• W4385667065 abstract "Background: Polycythemia Vera (PV) is initiated and maintained by mutant HSCs clones that acquired the JAK2V617F mutation and drive erythrocytosis in patients. So far, only Pegylated Interferon alpha (Peg-IFN-α) demonstrates a durable molecular response in the clinic; however, it is often associated with side effects leading to therapy discontinuation. Previous works suggest that Peg-IFN-α may deplete mutant HSCs by inducing their entry into cell cycle, DNA damage and subsequent exhaustion. This indicates that quiescence of mutant HSCs may be a vulnerable biological feature targeted by Peg-IFN-α. However, it has not been demonstrated that dormancy exists in the context of hematological malignancies, nor whether such cells are relevant to disease propagation and therapy resistance. Determining whether dormancy is a protective factor exploited by mutant HSCs to sustain disease and evade therapy may identify new therapeutic options to treat MPNs. Aims: The aim of the work is to provide a functional characterization of the biological relevance of dormant JAK2V617F-mutant HSCs in disease propagation and therapy resistance in a mouse model of PV. Methods: We have employed a novel transgenic mouse model that combines the knock-in of JAK2V617F mutation with the incorporation of the fusion protein histone H2B-GFP into the chromatin of HSCs. By using this model, which recapitulates a PV-like phenotype and allows the tracking of past replication history at a single HSC level, we have performed label-retention assays to formally interrogate the existence of long-term dormant mutant HSCs and their response to therapy. Results: Our results show that a rare subpopulation of mutant HSCs persists in a dormant state for up to 20 weeks post chase, despite the constitutively active JAK-STAT signaling. Moreover, our preliminary transplantation data supports the concept that dormant mutant HSCs may be responsible for disease propagation. Upon treatment with Fedratinib alone, dormant mutant HSCs persist, while treatment with a standard dose of Peg-IFN-α depletes these cells. Strikingly, while low dose Peg-IFN-α had no effect on dormant HSCs, the combination of Fedratinib and low-dose Peg-IFN-α synergized to deplete the dormant HSCs while also promoting a hematologic response. This suggests that low dose therapy with Peg-IFN-α can effectively deplete disease propagating HSCs when used in concert with Fedratinib, potentially circumventing the Peg-IFN-α-associated side effects. Summary/Conclusion: We have made the first characterization of dormant PV HSCs, that are able to maintain a quiescent state in vivo for more than four months, despite the presence of constitutive Jak2 signaling. Our preliminary data also indicates that these cells are relevant for disease propagation and that they are resistant to pharmacologic inhibition of Jak2 signaling. We hypothesize that dormancy might represent a state where mutant HSCs are no longer reliant on constitutive Jak2 signaling for survival. Importantly, combination treatment with Fedratinib and low-dose Peg-IFN-α produced a molecular response equivalent to that achieved using the standard dose of Peg-IFN-α, suggesting that low dose Peg-IFN-α can render these dormant HSCs again reliant on JAK2V617F signaling. We are currently using this model to establish how the status of cellular dormancy is maintained in a sub-set of HSCs in the face of constitutive JAK2 signaling, since this may identify additional therapeutic strategies to target this therapy-resistant cell population. Keywords: Interferon alpha, Hematopoietic stem cell, Myeloproliferative disorder" @default.
• W4385667065 created "2023-08-09" @default.
• W4385667065 creator A5011338293 @default.
• W4385667065 creator A5013603627 @default.
• W4385667065 creator A5018520078 @default.
• W4385667065 creator A5040159425 @default.
• W4385667065 creator A5066631249 @default.
• W4385667065 creator A5067898898 @default.
• W4385667065 date "2023-08-01" @default.
• W4385667065 modified "2023-10-14" @default.
• W4385667065 title "S208: RELEVANCE OF DORMANT CANCER STEM CELLS IN DISEASE PROPAGATION AND THERAPY RESISTANCEIN JAK2V617F-DRIVEN MPN." @default.
• W4385667065 doi "https://doi.org/10.1097/01.hs9.0000967744.64762.bd" @default.
• W4385667065 hasPublicationYear "2023" @default.
• W4385667065 type Work @default.
• W4385667065 citedByCount "0" @default.
• W4385667065 crossrefType "journal-article" @default.
• W4385667065 hasAuthorship W4385667065A5011338293 @default.
• W4385667065 hasAuthorship W4385667065A5013603627 @default.
• W4385667065 hasAuthorship W4385667065A5018520078 @default.
• W4385667065 hasAuthorship W4385667065A5040159425 @default.
• W4385667065 hasAuthorship W4385667065A5066631249 @default.
• W4385667065 hasAuthorship W4385667065A5067898898 @default.
• W4385667065 hasBestOaLocation W43856670651 @default.
• W4385667065 hasConcept C104317684 @default.
• W4385667065 hasConcept C121608353 @default.
• W4385667065 hasConcept C143065580 @default.
• W4385667065 hasConcept C151730666 @default.
• W4385667065 hasConcept C203014093 @default.
• W4385667065 hasConcept C2779343474 @default.
• W4385667065 hasConcept C2781230642 @default.
• W4385667065 hasConcept C28328180 @default.
• W4385667065 hasConcept C502942594 @default.
• W4385667065 hasConcept C54355233 @default.
• W4385667065 hasConcept C86803240 @default.
• W4385667065 hasConcept C95444343 @default.
• W4385667065 hasConceptScore W4385667065C104317684 @default.
• W4385667065 hasConceptScore W4385667065C121608353 @default.
• W4385667065 hasConceptScore W4385667065C143065580 @default.
• W4385667065 hasConceptScore W4385667065C151730666 @default.
• W4385667065 hasConceptScore W4385667065C203014093 @default.
• W4385667065 hasConceptScore W4385667065C2779343474 @default.
• W4385667065 hasConceptScore W4385667065C2781230642 @default.
• W4385667065 hasConceptScore W4385667065C28328180 @default.
• W4385667065 hasConceptScore W4385667065C502942594 @default.
• W4385667065 hasConceptScore W4385667065C54355233 @default.
• W4385667065 hasConceptScore W4385667065C86803240 @default.
• W4385667065 hasConceptScore W4385667065C95444343 @default.
• W4385667065 hasIssue "S3" @default.
• W4385667065 hasLocation W43856670651 @default.
• W4385667065 hasLocation W43856670652 @default.
• W4385667065 hasOpenAccess W4385667065 @default.
• W4385667065 hasPrimaryLocation W43856670651 @default.
• W4385667065 hasRelatedWork W1969421403 @default.
• W4385667065 hasRelatedWork W2040079807 @default.
• W4385667065 hasRelatedWork W2064207257 @default.
• W4385667065 hasRelatedWork W2150065613 @default.
• W4385667065 hasRelatedWork W2156423843 @default.
• W4385667065 hasRelatedWork W2156674132 @default.
• W4385667065 hasRelatedWork W2928062689 @default.
• W4385667065 hasRelatedWork W3120507315 @default.
• W4385667065 hasRelatedWork W4246662077 @default.
• W4385667065 hasRelatedWork W4247436401 @default.
• W4385667065 hasVolume "7" @default.
• W4385667065 isParatext "false" @default.
• W4385667065 isRetracted "false" @default.
• W4385667065 workType "article" @default.